Skip to main content

Table 3 Principal outcome measures in patients according to type of surfactant and method of delivery

From: Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis

Outcome Number of trials Number of patients Heterogeneity P value Fixed-effects model [odds ratio (95% CI)] Random-effects model [odds ratio (95% CI)]
   Control Surfactanta Q statistic I 2    
Overall mortality 6 631 639 6.00 0.17 0.31 0.99 (0.79, 1.25) 0.97 (0.73, 1.30)
Method of delivery         
   Aerosolized [16,17] 2 378 381 0.48 0 0.49 0.99 (0.74, 1.32) -
   Intratracheal [18-20] 4 253 258 5.52 0.46 0.14 1.00 (0.69, 1.46) 0.87 (0.48, 1.58)
Type of surfactant         
   Synthetic [16,17] (no surfactant protein) 2 378 381 2.21 0.55 0.14 1.09 (0.74, 1.60) 1.08 (0.72, 1.64)
   Recombinant [19,20] (SP-C) 3 237 239 0.36 0 0.84 0.99 (0.74, 1.32) -
   Recombinant + bovine [18-20] (SP-B and SP-C) 4 253 258 5.52 0.46 0.14 1.00 (0.69, 1.46) 0.87 (0.48, 1.58)
  1. aIn the studies by Weg and colleagues [16], Gregory and colleagues [18], and Spragg and colleagues [19], those patients who received a comparable surfactant dose (the higher dose) were used for the pooled analysis.